Welcome to our dedicated page for Boundless Bio SEC filings (Ticker: BOLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Boundless Bio, Inc. filings document a clinical-stage oncology issuer focused on ecDNA-directed cancer therapeutics, with formal disclosures on operating results, research programs, and material events. Recent 8-K reports furnish quarterly and annual financial results and business updates for BBI-940, KOMODO-1, and the discontinued POTENTIATE program involving BBI-355 and BBI-825.
Its proxy and current reports also cover board composition, director elections, auditor ratification, stockholder voting results, and facility-related obligations, including lease-termination arrangements. These filings frame the company’s clinical-development disclosures, public-company governance, capital allocation, and operating obligations.
Boundless Bio, Inc. reported that investment entities managed by Tang Capital Management, associated with ten percent owner Kevin Tang, purchased a total of 4,863 shares of common stock in open market or private transactions at $2.44 per share between July 17 and July 21, 2026, through indirect ownership.
Tang Capital Management LLC and Kevin Tang, both reported as 10% owners of Boundless Bio, Inc., disclosed open‑market purchases of 63,969 shares of common stock on July 14–16, 2026 at weighted‑average prices between $2.41 and $2.44 per share.
After these transactions, Tang‑affiliated entities TCP, TCPI, TCP III and TCP IV beneficially own a combined 2,854,072 shares, including 654,055, 891,914, 654,048 and 654,055 shares respectively, in which Kevin Tang has a pecuniary interest through his roles with these entities.
Boundless Bio, Inc. ten percent owner entities associated with Kevin Tang reported open-market purchases of a total of 91,585 shares of Common Stock on July 9, 10 and 13, 2026, at weighted-average prices of $2.48, $2.43 and $2.42 per share, respectively. Following the latest transaction, investment vehicles managed by Tang Capital Management LLC, in which Kevin Tang has a pecuniary interest, beneficially own 2,790,103 shares of Boundless Bio common stock indirectly.
Boundless Bio, Inc. reported that entities associated with Tang Capital Partners made open-market purchases of a total of 57,210 shares of common stock over three days. The buys on July 6–8, 2026 were executed at weighted-average prices between $2.46 and $2.49 per share.
Following these transactions, the indirect holdings reported as "By LP" increased to 2,698,518 shares of Boundless Bio common stock. Footnotes state that various Tang Capital funds collectively beneficially own these shares and that Kevin Tang has a pecuniary interest in the positions.
Boundless Bio, Inc. reported insider activity involving entities affiliated with ARCH Venture funds and investment committee member Kristina Burow. On July 1, 2026, a cashless stock option exercise for 16,000 shares of common stock at $1.03 per share was completed, followed by an open-market sale of 16,000 shares at $2.49 per share, with net proceeds remitted to ARCH funds. The filing also shows indirect holdings of 1,181,766, 828,570 and 683,759 shares of common stock as of that date.
Boundless Bio, Inc. received a Form 4 from ARCH-affiliated entities detailing a cashless stock option exercise and same-day sale tied to director Kristina Burow’s compensation. A stock option for 16,000 shares of common stock was exercised at $1.03 per share and the resulting 16,000 shares were sold in an open-market transaction at $2.49 per share. According to the footnotes, the net proceeds from this exercise and sale were remitted to ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., and ARCH Venture Fund X Overage, L.P., which continue to report substantial indirect holdings of Boundless Bio common stock.
Boundless Bio, Inc. insider entities affiliated with Kevin Tang reported open-market purchases of a total of 107,463 shares of Common Stock at prices around $2.49–$2.60 per share over three days. The transactions were made indirectly through limited partnerships managed by Tang Capital Management, LLC.
Following these purchases, the reporting entities collectively beneficially own 2,641,308 shares of Boundless Bio Common Stock, as described in the filing’s ownership breakdown for Tang Capital Partners, LP and related entities. All reported trades were classified as open-market purchases, with no sales or derivative transactions disclosed.
Boundless Bio disclosed ownership by Tang-linked investors totaling 11.3%. The Schedule 13G states 2,533,845 shares are beneficially owned collectively by Tang Capital Management, Kevin Tang and affiliated entities, based on 22,474,777 shares outstanding as of June 15, 2026.
The filing lists shared voting and dispositive power across Tang Capital Management, Tang Capital Partners, Tang Capital Partners International, Tang Capital Partners III, Tang Capital Partners IV and Kevin Tang; signatures are dated June 29, 2026.
Boundless Bio, Inc. insider entities affiliated with Tang Capital reported multiple open-market purchases of Common Stock. Across June 25–29, 2026, they bought a net 286,333 shares at weighted-average prices generally between about $2.40 and $2.60 per share.
Individual trades ranged from 134 shares to 145,880 shares per transaction, with reported per-share prices such as $2.48, $2.47, $2.54, $2.55 and $2.56. The positions are held indirectly "By LP" through Tang Capital limited partnership vehicles.
According to the filing, Tang Capital-related entities beneficially own 580,669, 791,839, 580,668 and 580,669 shares in four affiliated vehicles, for an aggregate beneficial holding of 2,533,845 shares after these purchases. Kevin Tang has a pecuniary interest in these indirectly held shares.
Boundless Bio, Inc. insider filings show that entities affiliated with Tang Capital report initial beneficial ownership of the company’s common stock. The Form 3 indicates indirect holdings of 2,247,512 shares of common stock, held by limited partnership and corporate vehicles associated with Tang Capital.
Kevin Tang is described as the sole manager or director of these entities and has a pecuniary interest in the shares they beneficially own. The filing is an initial ownership report and does not show any new purchases or sales of Boundless Bio stock.